Recently, molecular‐targeted therapies for patients with metastatic RCC has become a widely recognized treatment, with approved agents including the multikinase inhibitor, sunitinib, and the mammalian target of rapamycin (mTOR) inhibitor, everolimus. This evidence concerns the gene MTOR and renal cell carcinoma.